Abiopharma

I-80 GOLD CORP. (IAUX) Reports the reporting period Financial Results I-80 GOLD CORP. (IAUX) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 1661
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 513506
  • anticipated in the March 2025
  • targeting 150,000 to 200,000 ounces of gold beginning in 2028
  • anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, if any, that the Company will derive therefrom. By their nature, forward looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company’s control, including: general economic and industry conditions; volatility of commodity prices, including the prices of gold and silver; title risks and uncertainties; the Company’s ability to access sufficient capital from internal and external sources, including by selling assets, restructuring debt or obtaining additional equity capital, on terms that may be onerous or highly dilutive; uncertainties related to the refurbishment of the Lone Tree Plant, including cost overruns and construction delays; risks related to third-party toll milling arrangements and processing delays; uncertainties regarding water management and groundwater inflows at Granite Creek; risks related to the conversion of mineral resources and the results of feasibility and other technical studies; risks associated with mineral exploration, development and mining operations generally; risks related to obtaining and maintaining required governmental, environmental and other regulatory approvals and permits, including under NEPA and the BLM process, on a timely basis or at all; environmental, health and safety risks; risks relating to the reliance on key personnel and contractors (including Hatch); changes in applicable laws, regulations or government policies in Canada and the United States; foreign exchange and interest rate fluctuations; litigation risks; and the other risk factors discussed under the heading “Risk Factors” in the Company’s Form 10-K for the fiscal year ended December 31, 2025